- Commitment to make life-saving products to treat life-threatening hypovolemia due to sepsis and blood loss available in Sub-Saharan Africa where there is outsized demand.
- Targeted $20M Series B Round to include Sub-Saharan Africa in product development.
- Partnering with Propelevate to drive Sub-Saharan Africa strategy.
KANSAS CITY, Mo., Feb. 22, 2024 /PRNewswire/ — Life sciences company Vivacelle Bio today announced Sub-Saharan Africa as a priority region for its life-saving alternative to fluid resuscitation to treat hypovolemia caused by severe sepsis, septic shock, or blood loss. Vivacelle Bio’s lifesaving cardiovascular support fluids (VBI-S and VBI-1), both comprised of phospholipid nanoparticles, can be used to treat the refractory hypovolemia and hypotension that occur in severe sepsis and septic shock, and used instead of blood to correct hypovolemia from blood loss such as after major vehicle collisions and postpartum hemorrhage. Vivacelle Bio is partnering with Propelevate to drive the Sub-Saharan Africa strategy, which is fully integrated into its Series B financing round.
PR Newswire, February 22, 2024, 08:30 ET
https://www.prnewswire.com/news-releases/vivacelle-bio-integrates-sub-saharan-africa-strategy-into-series-b-financing-round-302067989.html